LIPASE VARIANTS FOR PHARMACEUTICAL USE
The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LAMSA, MICHAEL YAVER, DEBBIE LARSEN, SIGNE ESKILDSEN SVENDSEN, ALLAN CHRISTENSEN, LARS LEHMANN HYLLING SKJOET, MICHAEL LUNDIN, NINA GREGORY, PETER COLIN |
| description | The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type IL The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of M pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Il est décrit lutilisation pharmaceutique de lipases relatives à la lipase de Thermomyces lanuginosus (Humicola lanuginosa) comprenant les acides aminés 1 à 269 de SEQ ID N° : 2, éventuellement en combinaison avec une protéase et/ou une amylase. Les exemples dindications médicales sont les suivants : traitement de troubles digestifs, insuffisance pancréatique exocrine (PEI), pancréatite, fibrose cystique, diabète de type I et/ou diabète de type II. Les lipases de linvention présentent, par exemple, une performance de digestion améliorée in vitro et une activité améliorée à un pH dans la plage neutre, une stabilité améliorée à un pH faible et sont stables vis-à-vis dune dégradation de protéase et/ou stables en présence de pepsine et de sels biliaires. Linvention concerne également des procédés de détermination de performance de digestion in vitro des lipases ainsi que certaines nouvelles variantes de la lipase de T. lanuginosus. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CA2961041C</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CA2961041C</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CA2961041C3</originalsourceid><addsrcrecordid>eNrjZFDz8QxwDHZVCHMM8nT0CwlWcPMPUgjwcAzydXR2DQ3xdHb0UQgNduVhYE1LzClO5YXS3Azybq4hzh66qQX58anFBYnJqXmpJfHOjkaWZoYGJobOxoRVAAA5FiKe</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>LIPASE VARIANTS FOR PHARMACEUTICAL USE</title><source>esp@cenet</source><creator>LAMSA, MICHAEL ; YAVER, DEBBIE ; LARSEN, SIGNE ESKILDSEN ; SVENDSEN, ALLAN ; CHRISTENSEN, LARS LEHMANN HYLLING ; SKJOET, MICHAEL ; LUNDIN, NINA ; GREGORY, PETER COLIN</creator><creatorcontrib>LAMSA, MICHAEL ; YAVER, DEBBIE ; LARSEN, SIGNE ESKILDSEN ; SVENDSEN, ALLAN ; CHRISTENSEN, LARS LEHMANN HYLLING ; SKJOET, MICHAEL ; LUNDIN, NINA ; GREGORY, PETER COLIN</creatorcontrib><description>The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type IL The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of M pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Il est décrit lutilisation pharmaceutique de lipases relatives à la lipase de Thermomyces lanuginosus (Humicola lanuginosa) comprenant les acides aminés 1 à 269 de SEQ ID N° : 2, éventuellement en combinaison avec une protéase et/ou une amylase. Les exemples dindications médicales sont les suivants : traitement de troubles digestifs, insuffisance pancréatique exocrine (PEI), pancréatite, fibrose cystique, diabète de type I et/ou diabète de type II. Les lipases de linvention présentent, par exemple, une performance de digestion améliorée in vitro et une activité améliorée à un pH dans la plage neutre, une stabilité améliorée à un pH faible et sont stables vis-à-vis dune dégradation de protéase et/ou stables en présence de pepsine et de sels biliaires. Linvention concerne également des procédés de détermination de performance de digestion in vitro des lipases ainsi que certaines nouvelles variantes de la lipase de T. lanuginosus.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS OR TEST PAPERS THEREFOR ; COMPOSITIONS THEREOF ; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROCESSES OF PREPARING SUCH COMPOSITIONS ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200714&DB=EPODOC&CC=CA&NR=2961041C$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200714&DB=EPODOC&CC=CA&NR=2961041C$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LAMSA, MICHAEL</creatorcontrib><creatorcontrib>YAVER, DEBBIE</creatorcontrib><creatorcontrib>LARSEN, SIGNE ESKILDSEN</creatorcontrib><creatorcontrib>SVENDSEN, ALLAN</creatorcontrib><creatorcontrib>CHRISTENSEN, LARS LEHMANN HYLLING</creatorcontrib><creatorcontrib>SKJOET, MICHAEL</creatorcontrib><creatorcontrib>LUNDIN, NINA</creatorcontrib><creatorcontrib>GREGORY, PETER COLIN</creatorcontrib><title>LIPASE VARIANTS FOR PHARMACEUTICAL USE</title><description>The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type IL The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of M pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Il est décrit lutilisation pharmaceutique de lipases relatives à la lipase de Thermomyces lanuginosus (Humicola lanuginosa) comprenant les acides aminés 1 à 269 de SEQ ID N° : 2, éventuellement en combinaison avec une protéase et/ou une amylase. Les exemples dindications médicales sont les suivants : traitement de troubles digestifs, insuffisance pancréatique exocrine (PEI), pancréatite, fibrose cystique, diabète de type I et/ou diabète de type II. Les lipases de linvention présentent, par exemple, une performance de digestion améliorée in vitro et une activité améliorée à un pH dans la plage neutre, une stabilité améliorée à un pH faible et sont stables vis-à-vis dune dégradation de protéase et/ou stables en présence de pepsine et de sels biliaires. Linvention concerne également des procédés de détermination de performance de digestion in vitro des lipases ainsi que certaines nouvelles variantes de la lipase de T. lanuginosus.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS OR TEST PAPERS THEREFOR</subject><subject>COMPOSITIONS THEREOF</subject><subject>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROCESSES OF PREPARING SUCH COMPOSITIONS</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZFDz8QxwDHZVCHMM8nT0CwlWcPMPUgjwcAzydXR2DQ3xdHb0UQgNduVhYE1LzClO5YXS3Azybq4hzh66qQX58anFBYnJqXmpJfHOjkaWZoYGJobOxoRVAAA5FiKe</recordid><startdate>20200714</startdate><enddate>20200714</enddate><creator>LAMSA, MICHAEL</creator><creator>YAVER, DEBBIE</creator><creator>LARSEN, SIGNE ESKILDSEN</creator><creator>SVENDSEN, ALLAN</creator><creator>CHRISTENSEN, LARS LEHMANN HYLLING</creator><creator>SKJOET, MICHAEL</creator><creator>LUNDIN, NINA</creator><creator>GREGORY, PETER COLIN</creator><scope>EVB</scope></search><sort><creationdate>20200714</creationdate><title>LIPASE VARIANTS FOR PHARMACEUTICAL USE</title><author>LAMSA, MICHAEL ; YAVER, DEBBIE ; LARSEN, SIGNE ESKILDSEN ; SVENDSEN, ALLAN ; CHRISTENSEN, LARS LEHMANN HYLLING ; SKJOET, MICHAEL ; LUNDIN, NINA ; GREGORY, PETER COLIN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CA2961041C3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS OR TEST PAPERS THEREFOR</topic><topic>COMPOSITIONS THEREOF</topic><topic>CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROCESSES OF PREPARING SUCH COMPOSITIONS</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>LAMSA, MICHAEL</creatorcontrib><creatorcontrib>YAVER, DEBBIE</creatorcontrib><creatorcontrib>LARSEN, SIGNE ESKILDSEN</creatorcontrib><creatorcontrib>SVENDSEN, ALLAN</creatorcontrib><creatorcontrib>CHRISTENSEN, LARS LEHMANN HYLLING</creatorcontrib><creatorcontrib>SKJOET, MICHAEL</creatorcontrib><creatorcontrib>LUNDIN, NINA</creatorcontrib><creatorcontrib>GREGORY, PETER COLIN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LAMSA, MICHAEL</au><au>YAVER, DEBBIE</au><au>LARSEN, SIGNE ESKILDSEN</au><au>SVENDSEN, ALLAN</au><au>CHRISTENSEN, LARS LEHMANN HYLLING</au><au>SKJOET, MICHAEL</au><au>LUNDIN, NINA</au><au>GREGORY, PETER COLIN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>LIPASE VARIANTS FOR PHARMACEUTICAL USE</title><date>2020-07-14</date><risdate>2020</risdate><abstract>The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type IL The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of M pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
Il est décrit lutilisation pharmaceutique de lipases relatives à la lipase de Thermomyces lanuginosus (Humicola lanuginosa) comprenant les acides aminés 1 à 269 de SEQ ID N° : 2, éventuellement en combinaison avec une protéase et/ou une amylase. Les exemples dindications médicales sont les suivants : traitement de troubles digestifs, insuffisance pancréatique exocrine (PEI), pancréatite, fibrose cystique, diabète de type I et/ou diabète de type II. Les lipases de linvention présentent, par exemple, une performance de digestion améliorée in vitro et une activité améliorée à un pH dans la plage neutre, une stabilité améliorée à un pH faible et sont stables vis-à-vis dune dégradation de protéase et/ou stables en présence de pepsine et de sels biliaires. Linvention concerne également des procédés de détermination de performance de digestion in vitro des lipases ainsi que certaines nouvelles variantes de la lipase de T. lanuginosus.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_CA2961041C |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS OR TEST PAPERS THEREFOR COMPOSITIONS THEREOF CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES OF PREPARING SUCH COMPOSITIONS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | LIPASE VARIANTS FOR PHARMACEUTICAL USE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T08%3A49%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LAMSA,%20MICHAEL&rft.date=2020-07-14&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECA2961041C%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |